Market Overview:
The global compensated cirrhosis type C market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of compensated cirrhosis type C, rising awareness about the disease, and technological advancements in the field of diagnostics and treatment. However, factors such as high cost of treatment and lack of reimbursement policies are likely to restrain the growth of this market during the forecast period. The global compensated cirrhosis type C market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into antagonist drugs, antiviral drugs corticosteroids chelating agents. Antagonist drugs are expected to dominate this market duringthe forecast period owingto their ability topreventfurther damage caused by toxins released by damaged liver cells. By application, it can be classified into retail pharmacy hospital pharmacy online pharmacy drug store among others.
Product Definition:
Compensated cirrhosis type C is a term used to describe the stage of liver disease in which the liver has begun to fail, but symptoms have not yet developed. This stage is important because it can be a warning sign that someone is at risk for developing more serious liver problems in the future.
Antagonist:
Antagonist is a drug that blocks the action of a particular drug and is used in cases where patient's body cannot produce enough natural opioids to fight pain. Antagonists can be selected based on their therapeutic class, for example, if an opioid is required for pain management then an antagonist like naloxone or buprenorphine would be more appropriate as they have similar chemical structures but different molecules attached at the end of them.
Antiviral Drugs:
Antiviral drugs are used to treat the complications of viral hepatitis and the diseases caused by the virus. The most common types of antiviral drugs used for treatment include nucleoside analogs, non-nucleoside analogs, and integrase inhibitors.
Application Insights:
Based on application, the market is segmented into retail pharmacy, hospital pharmacy, online pharmacy and drug store. The retail pharmacies dominate the overall industry owing to growing demand for cost-effective drugs coupled with rising health awareness among people is a key factor driving compensated cirrhosis type C market.
The hospital pharmacies are anticipated to grow at a lucrative rate over the forecast period due to increasing prevalence of chronic diseases such as cancer and heart diseases which require regular medication. Moreover, an increase in number of hospitals & healthcare centers along with rising geriatric population across the globe will further boost revenue generation in near future.
Regional Analysis:
North America dominated the global compensated cirrhosis type C market in 2017. The presence of a large number of manufacturers, rising prevalence of hepatitis, and high adoption rate for new treatment methods are some factors attributing to its largest share. In addition, increasing demand for generic drugs due to patent expirations is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in healthcare expenditure and growing awareness about HCV infection & transmission modes among people. Moreover, economic development coupled with improving healthcare infrastructure will also boost regional market growth during the same period.
Growth Factors:
- Increasing incidence of compensated cirrhosis type C due to rising alcohol consumption and hepatitis C infection rates.
- Growing demand for novel therapies and treatments for compensated cirrhosis type C, especially those that improve patient outcomes and quality of life.
- Increasing number of clinical studies being conducted on new therapies for compensated cirrhosis type C, which is expected to result in more approvals and wider use of these drugs in the future.
- Rising healthcare expenditure by governments and private insurers worldwide, which is likely to lead to increased funding for research into new treatments for compensated cirrhosis type C patients. 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Compensated Cirrhosis Type C Market Research Report
By Type
Antagonist, Antiviral Drugs, Corticosteroids, Chelating Agents
By Application
Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, Drug Store
By Companies
Gilead Sciences, Inc., AbbVie Inc., Novartis International AG, Intercept Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Alnylam Pharmaceuticals Inc., Cadila Healthcare Ltd, Sanofi S.A, Pfizer Inc., Sun Pharmaceutical Industries Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Compensated Cirrhosis Type C Market Report Segments:
The global Compensated Cirrhosis Type C market is segmented on the basis of:
Types
Antagonist, Antiviral Drugs, Corticosteroids, Chelating Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, Drug Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences, Inc.
- AbbVie Inc.
- Novartis International AG
- Intercept Pharmaceuticals, Inc.
- Novo Nordisk A/S
- Eli Lilly and Company
- Alnylam Pharmaceuticals Inc.
- Cadila Healthcare Ltd
- Sanofi S.A
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
Highlights of The Compensated Cirrhosis Type C Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antagonist
- Antiviral Drugs
- Corticosteroids
- Chelating Agents
- By Application:
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Drug Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Compensated Cirrhosis Type C Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Compensated cirrhosis type C is a form of cirrhosis caused by the body's inability to break down and remove toxins from the blood. This can lead to liver damage, scarring, and eventually death.
Some of the major companies in the compensated cirrhosis type c market are Gilead Sciences, Inc., AbbVie Inc., Novartis International AG, Intercept Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Alnylam Pharmaceuticals Inc., Cadila Healthcare Ltd, Sanofi S.A, Pfizer Inc., Sun Pharmaceutical Industries Limited.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Compensated Cirrhosis Type C Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Compensated Cirrhosis Type C Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Compensated Cirrhosis Type C Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Compensated Cirrhosis Type C Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Compensated Cirrhosis Type C Market Size & Forecast, 2018-2028
4.5.1 Compensated Cirrhosis Type C Market Size and Y-o-Y Growth
4.5.2 Compensated Cirrhosis Type C Market Absolute $ Opportunity
Chapter 5 Global Compensated Cirrhosis Type C Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Compensated Cirrhosis Type C Market Size Forecast by Type
5.2.1 Antagonist
5.2.2 Antiviral Drugs
5.2.3 Corticosteroids
5.2.4 Chelating Agents
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Compensated Cirrhosis Type C Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Compensated Cirrhosis Type C Market Size Forecast by Applications
6.2.1 Retail Pharmacy
6.2.2 Hospital Pharmacy
6.2.3 Online Pharmacy
6.2.4 Drug Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Compensated Cirrhosis Type C Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Compensated Cirrhosis Type C Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Compensated Cirrhosis Type C Analysis and Forecast
9.1 Introduction
9.2 North America Compensated Cirrhosis Type C Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Compensated Cirrhosis Type C Market Size Forecast by Type
9.6.1 Antagonist
9.6.2 Antiviral Drugs
9.6.3 Corticosteroids
9.6.4 Chelating Agents
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Compensated Cirrhosis Type C Market Size Forecast by Applications
9.10.1 Retail Pharmacy
9.10.2 Hospital Pharmacy
9.10.3 Online Pharmacy
9.10.4 Drug Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Compensated Cirrhosis Type C Analysis and Forecast
10.1 Introduction
10.2 Europe Compensated Cirrhosis Type C Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Compensated Cirrhosis Type C Market Size Forecast by Type
10.6.1 Antagonist
10.6.2 Antiviral Drugs
10.6.3 Corticosteroids
10.6.4 Chelating Agents
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Compensated Cirrhosis Type C Market Size Forecast by Applications
10.10.1 Retail Pharmacy
10.10.2 Hospital Pharmacy
10.10.3 Online Pharmacy
10.10.4 Drug Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Compensated Cirrhosis Type C Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Compensated Cirrhosis Type C Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Compensated Cirrhosis Type C Market Size Forecast by Type
11.6.1 Antagonist
11.6.2 Antiviral Drugs
11.6.3 Corticosteroids
11.6.4 Chelating Agents
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Compensated Cirrhosis Type C Market Size Forecast by Applications
11.10.1 Retail Pharmacy
11.10.2 Hospital Pharmacy
11.10.3 Online Pharmacy
11.10.4 Drug Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Compensated Cirrhosis Type C Analysis and Forecast
12.1 Introduction
12.2 Latin America Compensated Cirrhosis Type C Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Compensated Cirrhosis Type C Market Size Forecast by Type
12.6.1 Antagonist
12.6.2 Antiviral Drugs
12.6.3 Corticosteroids
12.6.4 Chelating Agents
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Compensated Cirrhosis Type C Market Size Forecast by Applications
12.10.1 Retail Pharmacy
12.10.2 Hospital Pharmacy
12.10.3 Online Pharmacy
12.10.4 Drug Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Compensated Cirrhosis Type C Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Compensated Cirrhosis Type C Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Compensated Cirrhosis Type C Market Size Forecast by Type
13.6.1 Antagonist
13.6.2 Antiviral Drugs
13.6.3 Corticosteroids
13.6.4 Chelating Agents
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Compensated Cirrhosis Type C Market Size Forecast by Applications
13.10.1 Retail Pharmacy
13.10.2 Hospital Pharmacy
13.10.3 Online Pharmacy
13.10.4 Drug Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Compensated Cirrhosis Type C Market: Competitive Dashboard
14.2 Global Compensated Cirrhosis Type C Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences, Inc.
14.3.2 AbbVie Inc.
14.3.3 Novartis International AG
14.3.4 Intercept Pharmaceuticals, Inc.
14.3.5 Novo Nordisk A/S
14.3.6 Eli Lilly and Company
14.3.7 Alnylam Pharmaceuticals Inc.
14.3.8 Cadila Healthcare Ltd
14.3.9 Sanofi S.A
14.3.10 Pfizer Inc.
14.3.11 Sun Pharmaceutical Industries Limited
